US healthcare contract development and manufacturing organization (CDMO) market was valued at $171.3 billion in 2025 and is growing at a CAGR of 6.4% during the forecast period 2026-2035. The US healthcare contract development and manufacturing organization (CDMO) market is experiencing steady growth as pharmaceutical and biotechnology companies increasingly outsource drug development and manufacturing to specialized partners. Rising demand for complex therapies, including biologics, sterile injectables, and high-potency small molecules, is driving the need for advanced technical capabilities and flexible manufacturing solutions. CDMOs are focusing on expanding their capacity, adopting automation, and implementing digital quality systems to improve efficiency and compliance. Long-term collaborations are becoming more common, as companies seek reliable partners to navigate regulatory complexities and accelerate time-to-market. Additionally, there is growing emphasis on localized manufacturing within the US to strengthen supply chain resilience and meet domestic demand. Overall, the market is evolving toward integrated, end-to-end service offerings that combine development, analytical testing, and commercial-scale production.
Browse the full report description of “US Healthcare Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report by Services (Contract Development and Contract Manufacturing) Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/us-healthcare-cdmo-market
US Healthcare CDMO Market Driven by Global API Sourcing
The limited presence of domestic API manufacturers underscores a strong reliance on global supply networks to support drug production. This dependence increases the role of overseas partners and specialized CDMOs in ensuring the consistent availability of key pharmaceutical ingredients. It influences sourcing strategies, long-term partnerships, and operational planning across the US pharmaceutical value chain. Regulatory compliance and quality management become critical as imported APIs dominate supply. As demand for complex therapies continues to grow, CDMOs play a central role in scaling manufacturing capabilities. Overall, this dynamic reinforces the strategic importance of CDMOs in strengthening resilience and continuity within the US healthcare market.
US Healthcare CDMO Market – Key Players Overview
The key players in the healthcare CDMO market are Thermo Fisher Scientific Inc., Lonza Group AG, WuXi AppTec Co., Ltd., WuXi Biologics Co., Ltd., and Eurofins Scientific SE, among others. These companies focus on providing comprehensive development and manufacturing solutions that span early-stage research, clinical trial production, and commercial-scale manufacturing. The market is increasingly driven by the demand for specialized services such as sterile injectables, high-potency compounds, and complex biologics. Investment in advanced technologies, automation, and quality systems is central to maintaining regulatory compliance and operational efficiency. Overall, competition is shaped by the ability to deliver integrated, flexible, and high-quality services across multiple therapy areas.
Market Coverage
Key questions addressed by the report.
US Healthcare CDMO Market Report Segment
By Services
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-healthcare-cdmo-market